ICARES Medicus, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 10, 2022
Share
ICARES Medicus, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 124.24 million compared to TWD 95.48 million a year ago. Net income was TWD 27.34 million compared to TWD 8.53 million a year ago. Basic earnings per share from continuing operations was TWD 0.81 compared to TWD 0.25 a year ago. Diluted earnings per share from continuing operations was TWD 0.8 compared to TWD 0.25 a year ago.
For the six months, sales was TWD 243.37 million compared to TWD 179.44 million a year ago. Net income was TWD 57.03 million compared to TWD 14.72 million a year ago. Basic earnings per share from continuing operations was TWD 1.69 compared to TWD 0.44 a year ago. Diluted earnings per share from continuing operations was TWD 1.68 compared to TWD 0.44 a year ago.
Icares Medicus Inc is a Taiwan-based company mainly engaged in the authorization of high-end medical material surface treatment technology. The Company is also involved in the sale of surface treatment formulations and provision of customer surface treatment processing services, as well as the research and development, manufacture and sale of artificial lens and its implantation system. The Company's product revenue is mainly divided into three categories. The royalty income comes from the authorization of implantation/invasive high-end medical material surface treatment technology. The technical service income mainly includes implantation/invasive high-end medical surface treatment services, provision of medical coatings and foundry of artificial lens implantation systems. The sales of medical materials mainly include the sales of medical materials surface inspection equipment and other products. The Company distributes its products in domestic and overseas markets.
ICARES MEDICUS, INC. 